Research & Development Braeburn is committed to supporting independent scientific research and medical education.

Research & Development

Our research is focused on four different areas: opioid use disorder, chronic pain, schizophrenia and spasticity.

Opioid Use Disorder and Chronic Pain

Buprenorphine

Buprenorphine maintenance treatment is currently considered the gold standard in opioid use disorder treatment, with more than one million patients receiving buprenorphine in the U.S. and Europe. The medication reduces cravings, and the risk of relapse from opioid overdose.

Buprenorphine Granisetron Combination

Buprenorphine has been shown to be an effective treatment for pain and granisetron, is a widely used drug to treat nausea and vomiting. The combination is under investigation for the potential treatment of acute post-operative pain, nausea and vomiting.

Schizophrenia

Risperidone

Risperidone is an atypical (or second-generation) antipsychotic, it was first approved for treatment of schizophrenia by the FDA in 1994. Risperidone is currently marketed in oral and injectable formulations. The World Health Organization includes risperidone on its List of Essential Medicines, a list of the most important medications needed in a basic health system.

Spasticity

Tizanidine

Tizanidine is used to help relax certain muscles in the body. It relieves spasms, cramping, and tightness of the muscles caused by medical problems, such as multiple sclerosis or certain injuries to the spine. Tizanidine does not cure these conditions but may allow other treatment, such as physical therapy, to be more helpful in improving them.

Technologies

Fluid Crystal

The FluidCrystal technology, developed by Camurus, is an injectable drug delivery platform. This long-acting injectable technology offers continuous drug delivery from 1- 7 days to one month, and consists of a liquid lipid solution, which on contact with the body transforms to a liquid crystalline gel. This gel depot effectively encapsulates the drug compound, which is slowly and steadily released as the depot biodegrades. The technology also allows for a high drug load in a smaller injection volume.

ProNeura™

Titan Pharmaceutical’s ProNeura™ technology is utilized in the Probuphine® implant. The technology consists of a small, solid rod made from a mixture of ethylene-vinyl acetate co-polymer (EVA) matrix and a drug substance. ProNeura™ products are subdermal implants that are ideal for treating chronic diseases for which the maintenance of stable medication levels could offer advantages over other routes of administration. The implant is placed subcutaneously, in the inner part of a patient’s upper arm, during a procedure performed in the healthcare providers office. In the Probuphine implant, that drug substance is buprenorphine. Buprenorphine is released slowly for up to six months into the patient’s body at continuous levels through the process of diffusion from the implant. This results in a stable level of medication in the blood, similar to intravenous administration.

MedLaunch Technology

The implant platform technology enables subcutaneous insertion of a cylindrical, non-biodegradable, flexible polymer that can be used to deliver long-acting formulations of daily, oral drugs. This innovative technology allows for near zero-order release providing the patient with a continuous and consistent level of medication over the course of a six-month to one year treatment regimen. The polymer membrane controls the rate of diffusion of the drug substance, thereby providing immediate release while improving drug delivery via controlled release. This technology is currently being used in development of the six-month risperidone implant and the tizanidine implant.